Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 28 of 58, showing 10 Applications out of 576 total, starting on record 271, ending on 280

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

271.

ECCT/21/08/02   IPrEP Men\'s Study
    IPrEP Men’s Study: Expanding the reach of prevention for men in Kisumu, Kenya   
Principal Investigator(s)
1. Kawango Agot
2. Wafaa El-Sadr
Site(s) in Kenya
Kisumu Impact Research and Development Organization (K-IRDO) CRS
 
11-11-2021 View

272.

ECCT/21/07/01   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell DiseaseA Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Jessie Nyokabi Githanga
Site(s) in Kenya
1. Strathmore University Medical Center (Nairobi City county)
2. KEMRI Kondele children\'S Hospital (Kisumu county)
3. Gertrude\'s Children\'s Hospital (Nairobi City county)
 
10-11-2021 View

273.

ECCT/21/09/06   The PrEDIRA Study
    PILOTING HIV PRE-EXPOSURE PROPHYLAXIS (PREP) INTEGRATION INTO SERVICES FOR EARLY PREGNANCY LOSS   
Principal Investigator(s)
1. Prof. Elizabeth Bukusi
2. Dr. Nelly Mugo
3. Renee Heffron
Site(s) in Kenya
1. KEMRI RCTP (Kisumu county)
2. PARTNERS IN HEALTH RESEARCH AND DEVELOPMENT - THIKA (Kiambu county)
 
10-11-2021 View

274.

ECCT/21/05/04   Multi-nutrients in ADHD
    Broad spectrum micronutrient supplementation in the management of ADHD symptoms:a clinical trial   
Principal Investigator(s)
1. Maureen Muthoni Njoroge
Site(s) in Kenya
Kenyatta National Hospital
 
10-11-2021 View

275.

ECCT/21/07/06   GBT132_Inclacumab-Ps 3 Trial
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Fredrick Asirwa Chite
2. Videlis N Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Strathmore University Medical Centre (Nairobi City county)
 
09-11-2021 View

276.

ECCT/21/07/05   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa       
Principal Investigator(s)
1. Dr Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. KEMRI Walter Reed Project (Kericho county)
3. Moi University Clinical Research Centre (Uasin Gishu county)
 
09-11-2021 View

277.

ECCT/21/07/03   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Prof Jessie N Githanga
2. Fredrick Sirwa Chite
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
08-11-2021 View

278.

ECCT/21/04/01   FujiLAM Study
    Diagnostic performance of a novel lipoarabinomannan test (FujiLAM) to detect tuberculosis in HIV-positive patients in Kenya   
Principal Investigator(s)
1. Helena Huerga
Site(s) in Kenya
Homabay County Teaching and Referral Hospital
 
04-11-2021 View

279.

ECCT/21/07/02   TALIOS
    A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
01-11-2021 View

280.

ECCT/21/06/01   ACTIV-2/A5401
    ACTIV-2/A5401 "Adaptive Platform Treatment Trial for Outpatients with COVID-19" (Adapt Out COVID)_   
Principal Investigator(s)
1. Charles Meja Kwobah
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
01-11-2021 View